Treatment Response in First-episode Schizophrenia

Schennach, Rebecca; Riedel, Michael; Musil, Richard; Möller, Hans

doi:10.9758/cpn.2012.10.2.78

Cited by 43 publications

(30 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it is important to note that the multi-component intervention showed a specific beneficial effect on negative symptoms, which in general show relatively poorer response to psychopharmacological treatment in patients with FEP. 40,41 It is not completely clear what drives the relationship between age at first contact and experimental treatment outcome in our sample. However, data showing that patients with age at onset 535 years were more often women, less frequently diagnosed with schizophrenia, less frequently unmarried and unemployed or a student may in part explain the moderating effect of age at first contact on treatment outcome in our sample.…”

Section: Discussionmentioning

confidence: 90%

Predictors and moderators of treatment outcome in patients receiving multi-element psychosocial intervention for early psychosis: Results from the GET UP pragmatic cluster randomised controlled trial

Lasalvia¹,

Bonetto²,

Lenzi³

et al. 2017

Br J Psychiatry

View full text Add to dashboard Cite

The GET UP multi-element psychosocial intervention proved to be superior to treatment as usual in improving outcomes in patients with first-episode psychosis (FEP). However, to guide treatment decisions, information on which patients may benefit more from the intervention is warranted.To identify patients' characteristics associated with (a) a better treatment response regardless of treatment type (non-specific predictors), and (b) a better response to the specific treatment provided (moderators).Some demographic and clinical variables were selected as potential predictors/moderators of outcomes at 9 months. Outcomes were analysed in mixed-effects random regression models. (Trial registration: ClinicalTrials.gov, NCT01436331)Analyses were performed on 444 patients. Education, duration of untreated psychosis, premorbid adjustment and insight predicted outcomes regardless of treatment. Only age at first contact with the services proved to be a moderator of treatment outcome (patients aged ⩾35 years had greater improvement in psychopathology), thus suggesting that the intervention is beneficial to a broad array of patients with FEP.Except for patients aged over 35 years, no specific subgroups benefit more from the multi-element psychosocial intervention, suggesting that this intervention should be recommended to all those with FEP seeking treatment in mental health services.

show abstract

Section: Discussionmentioning

confidence: 90%

Predictors and moderators of treatment outcome in patients receiving multi-element psychosocial intervention for early psychosis: Results from the GET UP pragmatic cluster randomised controlled trial

Lasalvia¹,

Bonetto²,

Lenzi³

et al. 2017

Br J Psychiatry

View full text Add to dashboard Cite

show abstract

“…In the present study, almost half of the patients achieved a robust treatment response (ie, ≥50% decrease in PANSS total score) by the end of the documentation period. Although there is no set cut-off in patients with first-episode schizophrenia, 19 it has been suggested that the most appropriate definition of response in schizophrenia research is a ≥50% improvement in PANSS total score, 20 , 21 given the generally favorable response to antipsychotic treatment in these patients. One analysis that was conducted to explore the predictive validity of early response in first-episode schizophrenia found that the best PANSS score cut-off to predict maintenance of response was 51.6%.…”

Section: Discussionmentioning

confidence: 99%

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia

Emsley¹,

Hargarter²,

Bergmans³

et al. 2017

NDT

View full text Add to dashboard Cite

BackgroundLong-acting antipsychotic therapy may be best suited for patients in the early stage of schizophrenia, when the most can be done before disease progression associated with poor adherence occurs. We explored the patterns of use of once-monthly paliperidone palmitate (PP1M), concomitant medication use, hospitalization, and clinical outcomes of adult, newly diagnosed patients with schizophrenia receiving continuous treatment with PP1M for at least 12 months.MethodsThis was an international, multicenter, exploratory, retrospective chart review of medical records of adult patients who were newly diagnosed (not more than 1 year before initiation of PP1M treatment) with schizophrenia and who had received continuous treatment with PP1M for ≥12 months in naturalistic clinical settings.ResultsA total of 84 (93.3%) patients were included in the analysis. All but one patient (98.8%, n=83) had received oral antipsychotic medication at least during the last month before the first PP1M administration. Three patients (3.6%) were newly hospitalized during the 12-month documentation period. The reason for hospitalization for all three was management of episode/relapse. A total of 79.2% of patients had a ≥20% improvement and 47.2% had a ≥50% improvement in Positive and Negative Syndrome Scale total score from baseline to endpoint. Half of patients (53.3%) showed a significant improvement, as reflected by an increase in Personal and Social Performance (PSP) total score of at least 7 points from baseline to endpoint (mean [SD] 11.9 [15.0] points; P<0.001). One quarter of patients (24.4%, n=11) moved from a PSP score of 31–70 (ie, moderate to marked functional impairment) at baseline to a PSP score of mild to no functional impairment (PSP score ≥71) at endpoint. Most adverse drug reactions were mild or moderate in severity.ConclusionContinuous treatment with PP1M over 12 months was associated with statistically significant and clinically meaningful improvements in psychotic symptoms, disease severity, and functional outcomes in patients with schizophrenia.

show abstract

“… 48 , 49) Therefore, clozapine should be considered when choosing antipsychotics for the early treatment of first-episode schizophrenic patients, especially in cases of non-response. 50) …”

Section: Discussionmentioning

confidence: 99%

Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison

Roh

Chang

Yoon

et al. 2015

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

ObjectiveEarly treatment choice is critical in first-episode schizophrenia-spectrum disorders. The purpose of this study was to describe prescribing trends of antipsychotics use in patients with first-episode schizophrenia in 2005 and 2010, respectively.MethodsWe reviewed the medical records of newly treated patients with schizophrenia from a university psychiatric hospital in 2005 (n=47) and 2010 (n=52). We defined patients as receiving a high antipsychotic dose if their ratio of prescribed daily dose (PDD) to defined daily dose (DDD) was greater than 1.5.ResultsThe rates of high-dose antipsychotic prescription were 61.7% and 53.8% in 2005 and 2010, respectively. The rates of antipsychotic polypharmacy were 34.6% in 2005 and 34.0% in 2010. The most common first-prescribed antipsychotics were (in descending order of prescription frequency) olanzapine, risperidone, aripiprazole, and haloperidol in 2005 and risperidone, quetiapine, paliperidone, and olanzapine in 2010. High-dose antipsychotics were significantly associated with antipsychotic poly-pharmacy (odds ratio=23.97; p<0.01). More individuals were treated with mood stabilizers in 2010 than in 2005 (p=0.003).ConclusionThe practice of prescribing high-dose antipsychotics and associated antipsychotic polypharmacy were common even for initial treatment of first-episode schizophrenia in 2005 and 2010. In 2010, the list of the most common first-prescribed antipsychotics changed, and the use of mood stabilizers increased in non-affective schizophrenia.

show abstract

Treatment Response in First-episode Schizophrenia

Cited by 43 publications

References 79 publications

Predictors and moderators of treatment outcome in patients receiving multi-element psychosocial intervention for early psychosis: Results from the GET UP pragmatic cluster randomised controlled trial

Predictors and moderators of treatment outcome in patients receiving multi-element psychosocial intervention for early psychosis: Results from the GET UP pragmatic cluster randomised controlled trial

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia

Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison

Contact Info

Product

Resources

About

Treatment Response in First-episode Schizophrenia

Cited by 43 publications

References 79 publications

Predictors and moderators of treatment outcome in patients receiving multi-element psychosocial intervention for early psychosis: Results from the GET UP pragmatic cluster randomised controlled trial

Predictors and moderators of treatment outcome in patients receiving multi-element psychosocial intervention for early psychosis: Results from the GET UP pragmatic cluster randomised controlled trial

Once-monthly paliperidone palmitate in early stage schizophrenia &ndash; a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia

Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison

Contact Info

Product

Resources

About

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia